<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03756064</url>
  </required_header>
  <id_info>
    <org_study_id>TCHP</org_study_id>
    <nct_id>NCT03756064</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer</brief_title>
  <official_title>Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer: a Single-arm, Ahead, Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy
      and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel and Carboplatin versus
      placebo and trastuzumab plus docetaxel and Carboplatin given as neoadjuvant treatment in HER2
      positive early stage or locally advanced breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesized that the experimental group (Pyrotinib+Trastuzumab+Docetaxel+
      Carboplatin) could have a higher Pathological Complete Response (pCR) rate than the control
      group (Placebo +Trastuzumab+Docetaxel+ Carboplatin) in neoadjuvant chemotherapy.

      It is proposed that 100 participants will be enrolled in this study. The target population is
      women with early breast cancer (stage of T1-4N0-3M0) who are eligible for primary systemic
      therapy.

      The primary objective of the trial is to determine the pCR rate. The secondary objective of
      the trial is to determine the Event-free survival(EFS), Disease-free Survival (DFS), Distance
      Disease-free Survival (DDFS), Objective Response Rate (ORR) rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental: Pyrotinib (400mg orally daily)+Trastuzumab (8mg/kg iv load followed by 6mg/kg iv 3-weekly)+Docetaxel (75mg/m2)+ Carboplatin(AUC=5), for a total of 6 cycles.
Placebo Comparator: Placebo Oral Tablet (400mg orally daily)+Trastuzumab (8mg/kg iv load followed by 6mg/kg iv 3-weekly)+Docetaxel (75mg/m2)+ Carboplatin(AUC=5), for a total of 6 cycles.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>Following surgery until Year 3</time_frame>
    <description>Event-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>Following surgery until Year 3</time_frame>
    <description>Disease-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DDFS</measure>
    <time_frame>Following surgery until Year 3</time_frame>
    <description>Distance Disease-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Baseline up to cycle 4 (assessed at Baseline, at the time of pre-surgery)up to approximately 12 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neoplasm, Breast</condition>
  <condition>Breast Diseases</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pyrotinib+Trastuzumab+Docetaxel +Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Tablet+Trastuzumab+Docetaxel +Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>Pyrotinib: 400mg orally daily</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel: 75mg/m2 for a total of 6 cycles</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin: AUC=5 for a total of 6 cycles</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo Oral Tablet: 400mg orally daily</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. female patients, 18 years ≤ age ≤ 80 years；

          2. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1

          3. Histologically confirmed invasive breast cancer（early stage or locally advanced）

          4. HER2 positive (HER2+++ by IHC or FISH+)

          5. Known hormone receptor status.

          6. Cardiovascular: Baseline left ventricular ejection fraction (LVEF)≥55% measured by
             ECHO

          7. Signed informed consent form (ICF)

        Exclusion Criteria:

          1. Metastatic disease (Stage IV) or inflammatory breast cancer

          2. Previous or current history of malignant neoplasms, except for curatively treated:
             Basal and squamous cell carcinoma of the skin, Carcinoma in situ of the cervix.

          3. Clinically relevant cardiovascular disease: Known history of uncontrolled or
             symptomatic angina, clinically significant arrhythmias, congestive heart failure,
             transmural myocardial infarction, uncontrolled hypertension ≥180/110);

          4. Unable or unwilling to swallow tablets.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ding Xiaowen, DR.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ding Xiaowen, DR.</last_name>
    <phone>+86 13588054604</phone>
    <email>dingxw@zjcc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ding Yuqin</last_name>
    <phone>+86 13588255651</phone>
    <email>13588255651@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaowen ding, Dr.</last_name>
      <phone>+8613588054604</phone>
      <email>dingxw@zjcc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

